Fate Therapeutics’ (NASDAQ:FATE) multipronged CAR NK approach could address gaps left by single-target CAR-T therapies in B cell malignancies and chronic lymphocytic leukemia (CLL), experts said. This multiantigen targeted approach could limit antigen escape, which has been implicated in disease relapse, they added.
One of Fate’s lead products, FT596, consists of an hnCD16 receptor, a CAR-targeting CD19, and an IL-15 fusion protein. Experts found the NKG2D focus rational since the efficacy can be tumor independent. Moreover, experts considered Fate’s multitargeted approach as particularly advantageous since it could avoid antigen escape as is seen with CD19 CAR-T therapies like Novartis’ (SIX:NOVN) Kymriah (tisagenlecleucel). While therapies like FT596 are being studied in a relapsed/refractory population, experts said there is significant potential to explore multitargeted approaches before early single-antigen cell therapies.
Phase I (NCT04245722) FT596 results in B-cell lymphomas/CLL are expected at the American Society of Hematology (ASH) meeting in December or an investor meet in early 2021, as per an analyst report.